drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, gene-modified bispecific CD19/CD20-directed CAR T-cell therapy designed to deplete B-lineage cells to suppress B-cell–driven autoimmunity in refractory SLE and lupus nephritis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a bispecific CAR targeting CD19 and CD20 on B-lineage cells; engagement activates the CAR T cells to kill and deplete B cells and plasmablasts, reducing autoantibody production and B cell–driven autoimmunity in SLE and lupus nephritis.
drug_name
IMPT-514
nct_id_drug_ref
NCT06153095